Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast-enhanced CT

American Journal of Roentgenology

Volumn 194, Issue 1, 2010, Pages 157-165

  Smith, Andrew Dennis ^a   Lieber, Michael L ^a   Shah, Shetal N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Contrast enhanced CT; Metastatic renal cell carcinoma; Response assessment; Tumor attenuation; Tumor recurrence

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION ATTENUATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BENZENESULFONATES; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 74749099130     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2941     Document Type: Article

References (27)

1. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303-321
2. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27:187-193
3. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11: 37-42
4. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: 123-131
5. Michaelson MD. ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Cancer Treat Rev 2007; 33:381-390
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24
9. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178:1883-1887
10. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179:81-86
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
12. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14:1095-1097
13. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR 2007; 189:360-370
14. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764
15. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR 2002; 179:1059-1062
16. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 2004; 183:1619-1628
17. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759
18. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR 2007; 189:1450; [web]W324-W330
19. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007; 29:1338-1353
20. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13[suppl 2]:4-7
21. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892-898
22. Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002; 223:255-262
23. Fabel M, von Tengg-Kobligk H, Giesel FL, et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV: a feasibility study. Eur Radiol 2008; 18:1114-1122
24. Keil S, Behrendt FF, Stanzel S, et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices: comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008; 18:2456-2465
25. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999; 30:198-205
26. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000; 7:840-850
27. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR 2008; 191:133-139